DOCSLIB.ORG

Brigitta Teutsch ABOUT the LECTURER

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Brigitta Teutsch ABOUT the LECTURER PROGRESS REPORT I. 2020.11.23 Brigitta Teutsch ABOUT THE LECTURER Contacts: • E-mail: [email protected] 12-month fellowship programme Clinical scientific supervisor(s): • Bálint Erőss Brigitta • Nándor Faluhelyi Scientific methodology supervisor: Teutsch • Szilárd Váncsa Education supervisor: • Erika Pétervári TABLE OF CONTENTS I. Prevention and treatment of NSAID-induced small bowel enteropathies: A systematic review and meta-analysis • Project started: October 2020 PROJECTS II. Gastrointestinal Bleeding (GIB) Registry: cohort analysis • Project started: October 2020 III. Indications of Abdominal CT Angiography in clinical practice: observational study • Project started: November 2020 I. Prevention and treatment of NSAID-induced Project started: small bowel enteropathies: → October 2020 A systematic review and meta-analysis Expected submission date: → February 2021 BACKGROUND: → NSAIDs: some of the most commonly prescribed drugs → Small bowel enteropathy: • frequent (approximately 70%) among chronic NSAID consumers • common cause of obscure gastrointestinal bleedings → Treatment of NSAID-induced small bowel injuries: NO PROOF • high number of RCT in the topic • no meta-analysis • necessary to prevent complications QUESTIONS: Which medication is efficient and safe for the prevention or treatment of nonsteroidal anti-inflammatory drug (NSAID)-induced small intestinal injuries? P1: Patients taking NSAIDs and receiving treatment for the prevention of small bowel enteropathy P P2: Patients diagnosed with NSAID-induced small intestinal injury Medication for small bowel injury I (e.g. Rebamipide, Misoprostol, Irsogladine...) C Placebo/ Proton pump inhibitor O1: primary: mucosal integrity, secondary: drug-induced adverse events, cost of treatment O O2: primary: mucosal injury improvement, secondary: drug-induced adverse events, cost of treatment SYSTEMATIC SEARCH • Databases: MEDLINE (1104), Embase (1173), CENTRAL (1882), Scopus (1266) • Date of search: 20.10.2020 • Search key: (NSAID OR "non steroidal" OR nonsteroidal OR "anti inflammat*" OR antiinflammat* OR Aspirin OR Acetylsalicyl* OR Salicyl* OR Diflunisal OR Salsalate OR Butylpyrazolidine OR Phenylbutazone OR Mofebutazone OR Oxyphenbutazone OR Clofezone OR Kebuzone OR Suxibuzone OR “Acetic acid derivative*” OR Indometacin OR Sulindac OR Tolmetin OR Zomepirac OR Diclofenac OR Alclofenac OR Bumadizone ORA Etodolac prezentáció OR Lonazolac OR Fentiazac OR Acemetacin OR Difenpiramide OR Oxametacin OR Proglumetacin OR Ketorolac OR Aceclofenac OR Bufexamac OR “Enolic acid derivative*” OR Oxicam OR Piroxicam OR Tenoxicam OR Droxicam OR Lornoxicam OR Meloxicam OR “Propionic acid derivative*”alcíme OR Ibuprofen OR Naproxen OR Ketoprofen OR Fenoprofen OR Fenbufen OR Benoxaprofen OR Suprofen OR Pirprofen OR Flurbiprofen OR Indoprofen OR Tiaprofen OR “Tiaprofenic acid” OR Oxaprozin OR Ibuproxam OR Dexibuprofen OR Flunoxaprofen OR Alminoprofen OR Dexketoprofen OR Naproxcinod OR Vedaprofen OR Carprofen OR Tepoxalin OR “Anthranilic acid derivative*” OR Fenamate OR Mefenamate OR “Mefenamic acid” OR Tolfenamate OR “Tolfenamic acid” OR Flufenamate OR “Flufenamic acid” OR Meclofenamate OR “Meclofenamic acid” OR Flunixin OR Clonixin OR Coxib OR “COX-2 inhibit*” OR “Cyclooxygenase-2 inhibit*” OR Celecoxib OR Rofecoxib OR Valdecoxib OR Parecoxib OR Etoricoxib OR Lumiracoxib OR Polmacoxib OR Firocoxib OR Robenacoxib OR Mavacoxib OR Cimicoxib OR Deracoxib OR Enflicoxib OR Nabumetone OR “Niflumic acid” OR Azapropazone OR Glucosamine OR Benzydamine OR “Glycosaminoglycan polysulfate” OR Proquazone OR Orgotein OR Nimesulide OR Feprazone OR Diacerein OR Morniflumate OR Tenidap OR Oxaceprol OR “Chondroitin sulfate” OR Aminopropionitrile OR Grapiprant) AND (enteropath* OR enteritis OR "small bowel" OR "small intestin*" OR jejun* OR ileum OR ileal OR ileitis OR “intestinal injury” OR “intestinal lesion” OR “intestinal mucosal lesion” OR “bowel injury” OR “bowel lesion” OR “bowel mucosal lesion”) AND random* FLOWCHART OF SELECTION 542 N0 of records before the duplicate removal 5 334 N0 of records after the duplicate removal 0 Cohen’s Kappa: 0.88 108 N0 of eligible titles A prezentáció Cohen’s Kappa: 0.81 alcíme 56 N0 of eligible abstracts Cohen’s Kappa: 1.00 38 Data collection is under process ELIGIBLE FULL TEXTS: 11 4 5 4 4 10 Others: Ecabet sodium-2, Egualen sodium-2, Isinglass-2, Rifaximin-1, Polaprezinc-1, Rabeprazol-1, Mucoprotective drugs-1 II. Gastrointestinal Bleeding Registry: Project started: cohort analysis → November 2020 Expected submission date: → May 2021 GASTROINTESTINAL BLEEDINGS REGISTRY A prezentáció alcíme PRELIMINARY PATIENT ENROLLMENT FORMS ANALYSIS MGT CONFERENCE ABSTRACTS A prezentáció alcíme AIM: To describe the characteristics AIM: To give a descriptive analysis AIM: To give a descriptive analysis of and markers of renal dysfunction of of patients from our prospective patients from our prospective patients presenting with GIB. registry with a focus on symptoms registry with a focus on symptoms and etiology. and etiology. EFOP CONFERENCE ABSTRACTS AIM: To describe the characteristics and markers of renal dysfunction of patients presenting with GIB. AIM: To evaluate the mortality rate and describe the cause of death of the study population. A prezentáció alcíme AIM: To examine the connection between the common risk factors and GIB. AIM: To provide a descriptive analysis of body weight and BMI in patients with GIB. FUTURE PLANS ANALYSES AND TEST SAMPLES STORED IN THE BIOBANK JOIN OF 14th of December, 2020: HUNGARIAN → 300 patients AND FOREIGN INSTITUTIONS A prezentáció alcíme CLINICAL TRIALS Project started: III. Indications of Abdominal CT Angiography → November 2020 in clinical practice: observational study Expected submission date: → July 2021 ABDOMINAL CT-ANGIOGRAPHY Abdominal CT-angiography: → Fast detection and localisation of the bleeding site → Information about patients anatomy → Highly available → Minimally invasive → Lack of information regarding the indications ABDOMINAL CT-ANGIOGRAPHY Future plans: →Ethical approval →Retrospective data collection →CT scan reevaluation →Inclusion of multiple centers TABLE OF CONTENTS I. Systematic review and meta-analysis – data collection is under process • Expected submission date: February 2021 PROJECTS II. Registry analysis – patient enrollment is still ongoing • Expected submission date: May 2021 III. Indications of Abdominal CT Angiography in clinical practice: observational study - under ethical approval • Expected submission date: July 2021 THANK YOU FOR YOUR ATTENTION! QUESTIONS.
Load more

Recommended publications
  • Pain Management in Companion Animals
    CONTINUING EDUCATION TAP OUR APP Pain Management in Companion Animals Download “NCPA Mobile” Today! by Ann Philbrick, PharmD, BCPS Don’t be left out of the latest news affecting community pharmacy—download our new app, NCPA Mobile! Receive real-time updates, join the conversation on Twitter with a built-in feed, Jul. 1, 2015 (expires Jul. 1, 2018) and never miss out on breaking news affecting community pharmacy. Keep the Activity Type: Application-based app on your phone year-round for updates, news, alerts, and more from NCPA. To earn continuing education credit: ACPE Program 0207-0000-15-007-H01-P; 0207-0000-15-007-H01-T Upon successful completion of this article, the pharmacist should be able to: 1. Describe the process of pain in the dog and cat including identification of ways they express pain. 2. Describe the appropriate use, mechanism of action, and precautions for use of analgesics in the treatment of pain in dogs and cats. 3. Explain the key issues that impair the prevention of diversion in compan- ion animal owners. Upon successful completion of this article, the pharmacist should be able to: 1. Describe the process of pain in the dog and cat including identification of ways they express pain. To get the free NCPA Mobile app: 2. Describe the appropriate use, mechanism of action, and precautions for FREE ONLINE CE. To take advantage use of analgesics in the treatment of pain in dogs and cats. of free continuing pharmacy educa- iPhone and iPad users—search “NCPA 3. Explain the key issues that impair the prevention of diversion in compan- tion (CPE) for this program, pharma- ion animal owners.
    [Show full text]
  • Pain Management E-Book
    VetEdPlus E-BOOK RESOURCES Pain Management E-Book WHAT’S INSIDE Gabapentin and Amantadine for Chronic Pain: Is Your Dose Right? Grapiprant for Control of Osteoarthritis Pain in Dogs Use of Acupuncture for Pain Management Regional Anesthesia for the Dentistry and Oral Surgery Patient A SUPPLEMENT TO Laser Therapy for Treatment of Joint Disease in Dogs and Cats Manipulative Therapies for Hip and Back Hypomobility in Dogs E-BOOK PEER REVIEWED CONTINUING EDUCATION Gabapentin and Amantadine for Chronic Pain: Is Your Dose Right? Tamara Grubb, DVM, PhD, DACVAA Associate Professor, Anesthesia and Analgesia Washington State University College of Veterinary Medicine Pain is not always a bad thing, and all pain is not Untreated or undertreated pain can cause myriad the same. Acute (protective) pain differs from adverse effects, including but not limited to chronic (maladaptive) pain in terms of function insomnia, anorexia, immunosuppression, and treatment. This article describes the types of cachexia, delayed wound healing, increased pain pain, the reasons why chronic pain can be sensation, hypertension, and behavior changes difficult to treat, and the use of gabapentin and that can lead to changes in the human–animal amantadine for treatment of chronic pain. bond.2 Hence, we administer analgesic drugs to patients with acute pain, not to eliminate the protective portion but to control the pain ACUTE PAIN beyond that needed for protection (i.e., the pain Acute pain in response to tissue damage is often that negatively affects normal physiologic called protective pain because it causes the processes and healing). This latter type of pain patient to withdraw tissue that is being damaged decreases quality of life without providing any to protect it from further injury (e.g., a dog adaptive protective mechanisms and is thus withdrawing a paw after it steps on something called maladaptive pain.
    [Show full text]
  • Table S1: Sensitivity, Specificity, PPV, NPV, and F1 Score of NLP Vs. ICD for Identification of Symptoms for (A) Biome Developm
    Table S1: Sensitivity, specificity, PPV, NPV, and F1 score of NLP vs. ICD for identification of symptoms for (A) BioMe development cohort; (B) BioMe validation cohort; (C) MIMIC-III; (D) 1 year of notes from patients in BioMe calculated using manual chart review. A) Fatigue Nausea and/or vomiting Anxiety Depression NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.99 (0.93- 0.59 (0.43- <0.00 0.25 (0.12- <0.00 <0.00 0.54 (0.33- Sensitivity 0.99 (0.9 – 1) 0.98 (0.88 -1) 0.3 (0.15-0.5) 0.85 (0.65-96) 0.02 1) 0.73) 1 0.42) 1 1 0.73) 0.57 (0.29- 0.9 (0.68- Specificity 0.89 (0.4-1) 0.75 (0.19-1) 0.68 0.97 (0.77-1) 0.03 0.98 (0.83-1) 0.22 0.81 (0.53-0.9) 0.96 (0.79-1) 0.06 0.82) 0.99) 0.99 (0.92- 0.86 (0.71- 0.94 (0.79- 0.79 (0.59- PPV 0.96 (0.82-1) 0.3 0.95 (0.66-1) 0.02 0.95 (0.66-1) 0.16 0.93 (0.68-1) 0.12 1) 0.95) 0.99) 0.92) 0.13 (0.03- <0.00 0.49 (0.33- <0.00 0.66 (0.48- NPV 0.89 (0.4-1) 0.007 0.94 (0.63-1) 0.34 (0.2-0.51) 0.97 (0.81-1) 0.86 (0.6-0.95) 0.04 0.35) 1 0.65) 1 0.81) <0.00 <0.00 <0.00 F1 Score 0.99 0.83 0.88 0.57 0.95 0.63 0.82 0.79 0.002 1 1 1 Itching Cramp Pain NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.98 (0.86- 0.24 (0.09- <0.00 0.09 (0.01- <0.00 0.52 (0.37- <0.00 Sensitivity 0.98 (0.85-1) 0.99 (0.93-1) 1) 0.45) 1 0.29) 1 0.66) 1 0.89 (0.72- 0.5 (0.37- Specificity 0.96 (0.8-1) 0.98 (0.86-1) 0.68 0.98 (0.88-1) 0.18 0.5 (0-1) 1 0.98) 0.66) 0.88 (0.69- PPV 0.96 (0.8-1) 0.8 (0.54-1) 0.32 0.8 (0.16-1) 0.22 0.99 (0.93-1) 0.98 (0.87-1) NA* 0.97) 0.98 (0.85- 0.57 (0.41- <0.00 0.58 (0.43- <0.00 NPV 0.98 (0.86-1) 0.5 (0-1) 0.02 (0-0.08) NA* 1) 0.72) 1 0.72) 1 <0.00 <0.00 <0.00 F1 Score 0.97 0.56 0.91 0.28 0.99 0.68 1 1 1 *Denotes 95% confidence intervals and P values that could not be calculated due to insufficient cells in 2x2 tables.
    [Show full text]
  • Comparative Efficacy and Safety of Mavacoxib and Carprofen in The
    Paper Paper Comparative efficacy and safety of mavacoxib and carprofen in the treatment of canine osteoarthritis M Payne-Johnson, C Becskei, Y Chaudhry, M R Stegemann A multi-site, masked, randomised parallel group study employing a double dummy treatment design was performed in canine veterinary patients to determine the comparative efficacy and safety of mavacoxib and carprofen in the treatment of pain and inflammation associated with osteoarthritis for a period of 134 days. Treatments were administered according to their respective summaries of product characteristics. Of 139 dogs screened, 124 were suitable for study participation: 62 of which were dosed with mavacoxib and 62 with carprofen. Both treatments resulted in a very similar pattern of considerable improvement as indicated in all parameters assessed by both owner and veterinarian. The primary efficacy endpoint ‘overall improvement’ was a composite score of owner assessments after approximately six weeks of treatment. Both drugs were remarkably effective, with 57/61 (93.4 per cent) of mavacoxib-treated dogs and 49/55 (89.1 per cent) of carprofen-treated dogs demonstrating overall improvement and with mavacoxib’sefficacy being non-inferior to carprofen. The treatments had a similar safety profile as evidenced by documented adverse events and summaries of clinical pathology parameters. The positive clinical response to treatment along with the safety and dosing regimen of mavacoxib makes it an attractive therapy for canine osteoarthritis. Introduction convert arachidonic acid into prostaglandin H2, from which a Osteoarthritis (OA) is characterised by a degenerative, progres- series of prostanoids is derived; this can result in sensitisation of sive and irreversible deterioration of joints resulting in a nociceptive neurone terminals and with repeated stimulation decreased range of motion, pain, joint swelling and crepitus.
    [Show full text]
  • 268 Part 522—Implantation Or Injectable Dosage Form
    § 520.2645 21 CFR Ch. I (4–1–18 Edition) (ii) Indications for use. For the control 522.82 Aminopropazine. of American foulbrood (Paenibacillus 522.84 Beta-aminopropionitrile. larvae). 522.88 Amoxicillin. 522.90 Ampicillin injectable dosage forms. (iii) Limitations. The drug should be 522.90a Ampicillin trihydrate suspension. fed early in the spring or fall and con- 522.90b Ampicillin trihydrate powder for in- sumed by the bees before the main jection. honey flow begins, to avoid contamina- 522.90c Ampicillin sodium. tion of production honey. Complete 522.144 Arsenamide. treatments at least 4 weeks before 522.147 Atipamezole. main honey flow. 522.150 Azaperone. 522.161 Betamethasone. [40 FR 13838, Mar. 27, 1975, as amended at 50 522.163 Betamethasone dipropionate and FR 49841, Dec. 5, 1985; 59 FR 14365, Mar. 28, betamethasone sodium phosphate aque- 1994; 62 FR 39443, July 23, 1997; 68 FR 24879, ous suspension. May 9, 2003; 70 FR 69439, Nov. 16, 2005; 73 FR 522.167 Betamethasone sodium phosphate 76946, Dec. 18, 2008; 75 FR 76259, Dec. 8, 2010; and betamethasone acetate. 76 FR 59024, Sept. 23, 2011; 77 FR 29217, May 522.204 Boldenone. 17, 2012; 79 FR 37620, July 2, 2014; 79 FR 53136, 522.224 Bupivacaine. Sept. 8, 2014; 79 FR 64116, Oct. 28, 2014; 80 FR 522.230 Buprenorphine. 34278, June 16, 2015; 81 FR 48702, July 26, 2016] 522.234 Butamisole. 522.246 Butorphanol. § 520.2645 Tylvalosin. 522.275 N-Butylscopolammonium. 522.300 Carfentanil. (a) Specifications. Granules containing 522.304 Carprofen. 62.5 percent tylvalosin (w/w) as 522.311 Cefovecin.
    [Show full text]
  • Review Article
    REVIEW ARTICLE COLLAGEN METABOLISM COLLAGEN METABOLISM Types of Collagen 228 Structure of Collagen Molecules 230 Synthesis and Processing of Procollagen Polypeptides 232 Transcription and Translation 233 Posttranslational Modifications 233 Extracellular Processing of Procollagen and Collagen Fibrillogenesis 240 Functions of Collagen in Connective rissue 243 Collagen Degradation 245 Regulation of the Metabolism of Collagen 246 Heritable Diseases of Collagen 247 Recessive Dermatosparaxis 248 Recessive Forms of EDS 251 EDS VI 251 EDS VII 252 EDS V 252 Lysyl Oxidase Deficiency in the Mouse 253 X-Linked Cutis Laxa 253 Menke's Kinky Hair Syndrome 253 Homocystinuria 254 EDS IV 254 Dominant Forms of EDS 254 Dominant Collagen Packing Defect I 255 Dominant and Recessive Forms of Osteogenesis Imperfecta 258 Dominant and Recessive Forms of Cutis Laxa 258 The Marfan Syndrome 259 Acquired Diseases and Repair Processes Affecting Collagen 259 Acquired Changes in the Types of Collagen Synthesis 260 Acquired Changes in Amounts of Collagen Synthesized 263 Acquired Changes in Hydroxylation of Proline and Lysine 264 Acquired Changes in Collagen Cross-Links 265 Acquired Defects in Collagen Degradation 267 Conclusion 267 Bibliography 267 Collagen Metabolism A Comparison of Diseases of Collagen and Diseases Affecting Collagen Ronald R. Minor, VMD, PhD COLLAGEN CONSTITUTES approximately one third of the body's total protein, and changes in synthesis and/or degradation of colla- gen occur in nearly every disease process. There are also a number of newly described specific diseases of collagen in both man and domestic animals. Thus, an understanding of the synthesis, deposition, and turnover of collagen is important for the pathologist, the clinician, and the basic scientist alike.
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • A Review of the Effects of Pain and Analgesia on Immune System Function and Inflammation: Relevance for Preclinical Studies
    Comparative Medicine Vol 69, No 6 Copyright 2019 December 2019 by the American Association for Laboratory Animal Science Pages 520–534 Overview A Review of the Effects of Pain and Analgesia on Immune System Function and Inflammation: Relevance for Preclinical Studies George J DeMarco1* and Elizabeth A Nunamaker2 One of the most significant challenges facing investigators, laboratory animal veterinarians, and IACUCs, is how to bal- ance appropriate analgesic use, animal welfare, and analgesic impact on experimental results. This is particularly true for in vivo studies on immune system function and inflammatory disease. Often times the effects of analgesic drugs on a particu- lar immune function or model are incomplete or don’t exist. Further complicating the picture is evidence of the very tight integration and bidirectional functionality between the immune system and branches of the nervous system involved in nociception and pain. These relationships have advanced the concept of understanding pain as a protective neuroimmune function and recognizing pathologic pain as a neuroimmune disease. This review strives to summarize extant literature on the effects of pain and analgesia on immune system function and inflammation in the context of preclinical in vivo studies. The authors hope this work will help to guide selection of analgesics for preclinical studies of inflammatory disease and immune system function. Abbreviations and acronyms: CB,Endocannabinoid receptor; CD,Crohn disease; CFA, Complete Freund adjuvant; CGRP,Calcitonin gene-related
    [Show full text]
  • Survey of Pain Knowledge and Analgesia in Dogs and Cats by Colombian Veterinarians
    veterinary sciences Article Survey of Pain Knowledge and Analgesia in Dogs and Cats by Colombian Veterinarians Carlos Morales-Vallecilla 1, Nicolas Ramírez 1, David Villar 1,*, Maria Camila Díaz 1 , Sandra Bustamante 1 and Duncan Ferguson 2 1 Facultad de Ciencias Agrarias Universidad de Antioquia, Medellín 050010, Colombia; [email protected] (C.M.-V.); [email protected] (N.R.); [email protected] (M.C.D.); [email protected] (S.B.) 2 Department of Comparative Biosciences, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61802, USA; [email protected] * Correspondence: [email protected]; Tel.: +57-3178047381 Received: 6 December 2018; Accepted: 5 January 2019; Published: 10 January 2019 Abstract: A questionnaire study was conducted among 131 veterinarians practicing in the city of Medellin, Colombia, to assess views on pain evaluation and management in dogs and cats. When pain recognition and quantification abilities were used as a perceived competence of proper pain assessment, only 83/131 (63.4%, confidence interval (CI) 0.55–0.72) were deemed to have satisfactory skills, with the rest considered to be deficient. There were 49/131 (37.4) veterinarians who had participated in continuing education programs and were more confident assessing pain, with an odds ratio ( standard error) of 2.84 1.15 (p = 0.01; CI 1.27–6.32). In addition, the odds of using ± ± pain scales was 4.28 2.17 (p < 0.01, CI 1.58–11.55) greater if they had also participated in continuing ± education programs. The term multimodal analgesia was familiar to 77 (58.7%) veterinarians who also claimed to use more than one approach to pain control.
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]